13F Pro13F Pro

Avoro Capital Advisors LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1633313
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.7%$11.1B
  • Other0.3%$36.1M

AUM History

13fpro.ai/research/fund/avoro-capital-advisors-llc-1633313

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/avoro-capital-advisors-llc-1633313

Avoro Capital Advisors LLC 13F holdings — Q2 2026

$11.1B portfolio (+9.6% QoQ) · 26 holdings · Q2 2026 13F · top 10 are 80% of the stock portfolio

All holdings — Avoro Capital Advisors LLC (Q2 2026)

26 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
GPCR$GPCRStructure Therapeutics Inc.adr$351.8M—
XENE$XENEXenon Pharmaceuticals Inc.$348.7M—
DFTX$DFTXDefinium Therapeutics, Inc.$338.2M+44%
QURE$QUREuniQure N.V.$309.9M+13%
VERA$VERAVera Therapeutics, Inc.$245.6M-3%
TSHA$TSHATaysha Gene Therapies, Inc.$162.7M+10%
OCUL$OCULOCULAR THERAPEUTIX, INC$123.1M+2%
DMRA$DMRADamora Therapeutics, Inc.$98.4M—
COAG$COAGHemab Therapeutics Holdings, Inc.$70.7MNew
GHRS$GHRSGH Research PLC$48.4M—
VRDN$VRDNViridian Therapeutics, Inc.\DE$45.9M+67%
SEPN$SEPNSepterna, Inc.$44.8M—
AVTX$AVTXAvalo Therapeutics, Inc.$43.1M+65%
— FAETH THERAPEUTICS INC - COMMON$36.1MNew
WHWK$WHWKWhitehawk Therapeutics, Inc.$13.1M—

What changed in Q2 2026

Against the previous quarter's 13F: 2 new, 12 added to, 3 trimmed, 8 sold out. Share-count changes; largest moves by dollar size first.

New positions (2)

  • COAG$COAGHemab Therapeutics Holdings, Inc.$70.7M

    first bought this quarter

  • FAETH THERAPEUTICS INC - COMMON$36.1M

    first bought this quarter

Added to (12)

  • CYTK$CYTKCYTOKINETICS INC+50%

    now $425.9M · held 2 qtrs, 2 adds in a row

  • DFTX$DFTXDefinium Therapeutics, Inc.+44%

    now $338.2M · held 2 qtrs, 2 adds in a row

  • UTHR$UTHRUNITED THERAPEUTICS Corp+6%

    now $1.5B · held 10+ qtrs

  • ARWR$ARWRARROWHEAD PHARMACEUTICALS, INC.+6%

    now $925.6M · held 10+ qtrs

  • QURE$QUREuniQure N.V.+13%

    now $309.9M · held 7 qtrs

  • VRDN$VRDNViridian Therapeutics, Inc.\DE+67%

    now $45.9M · held 3 qtrs

+6 more in the Excel export

Trimmed (3)

  • RVMD$RVMDRevolution Medicines, Inc.-2%

    now $430.2M · held 3 qtrs

  • VERA$VERAVera Therapeutics, Inc.-3%

    now $245.6M · held 10+ qtrs

  • LXEO$LXEOLexeo Therapeutics, Inc.-21%

    now $6.9M · held 3 qtrs, 2 trims in a row

Sold out (8)

  • APLS$APLSApellis Pharmaceuticals, Inc.was $491.7M

    held 9+ qtrs

  • CNTA$CNTACentessa Pharmaceuticals plcwas $454.0M

    held 5 qtrs

  • TERN$TERNTerns Pharmaceuticals, Inc.was $300.2M

    held 1 qtr

  • SLNO$SLNOSOLENO THERAPEUTICS INCwas $77.0M

    held 9+ qtrs

  • ALKS$ALKSAlkermes plc.was $42.4M
  • UTHR$UTHRCALLUNITED THERAPEUTICS Corpwas $10.3M

+2 more in the Excel export

Firm AUM (Form ADV): $13.6B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Avoro Capital Advisors LLC has filed, 41 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Avoro Capital Advisors?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Avoro Capital Advisors's top 20 holdings: 47/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-5.1%

Value-weighted move of the 10 largest stock positions

Turnover

6%

Last quarter; 31% over the last 4

Top 10 weight

80%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

83%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Avoro Capital Advisors LLC disclosed 26 positions worth $11.1B in its Form 13F-HR for Q2 2026, led by $UTHR (UNITED THERAPEUTICS Corp) at 13.5% of the equity portfolio, followed by $ASND and $KRYS. During the quarter the fund opened 2 new positions and exited 8 — including a new stake in $COAG and a full exit from $APLS. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from Avoro Capital Advisors LLC’s Form 13F-HR filing with the SEC under CIK 1633313.

Funds like this

managers whose biggest positions overlap Avoro Capital Advisors's
RTW INVESTMENTS, LP$11.71B 13F book · 8 shared top holdingsMDGLARGXCELCCYTKBAKER BROS. ADVISORS LP$19.96B 13F book · 7 shared top holdingsMDGLKYMRRVMDCELCSiren, L.L.C.$4.94B 13F book · 10 shared top holdingsKYMRRVMDARWRXENEFirst Turn Management, LLC$934.72M 13F book · 8 shared top holdingsUTHRRVMDCYTKCELCSoleus Capital Management, L.P.$2.90B 13F book · 4 shared top holdingsKRYSUTHRCELCAVTXDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 7 shared top holdingsRVMDCELCUTHRVERA

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Avoro Capital Advisors LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Avoro Capital Advisors LLC (SEC CIK: 1633313), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Avoro Capital Advisors LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.